More notable recent Landstar System, Inc. Kistler Tiffany Companies LLC now owns 3,673 shares of the company's stock worth $122,000 after acquiring an additional 1,571 shares during the period. Over the past month the firm's stock is -24.94%, -49.62% for the last quarter, -46.83% for the past six-months and -56.50% for the a year ago.
Teva Chairman Sol Barer said the new chief executive has everything that the firm was looking for in a new leader: Global pharmaceutical experience, a restructuring background and knowledge of generic and specialty medicines. The institutional investor held 715,483 shares of the transportation company at the end of 2016Q4, valued at $61.03 million, down from 721,988 at the end of the previous reported quarter. The dividend payment will be $0.275 per share for the quarter which comes to $1.10 on an annualized basis.
Meiji Yasuda Asset Management Co Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, Holdings Channel reports. Sphera Funds Management Ltd bought 120,000 shares as the company's stock declined 15.11% while stock markets rallied. PPG Industries, Inc. (NYSE:PPG) has risen 1.03% since September 12, 2016 and is uptrending. About 322,549 shares traded. While the stock price moved along with the volume change, shares are touching $19.29.
"Schultz will be Teva's fourth CEO over the last six years, and we think Teva must stabilize its executive ranks to execute on its turnaround strategy and lower its high debt level, now at $34 billion", said analyst Jeffrey Loo, with CFRA Research, in a client note. The company has market cap of $18.98 billion. The value of the company's investment in Teva Pharmaceutical Industries decreased from $11,751,000 to $9,479,000 a change of $2,272,000 since the last quarter.
Teva Pharmaceutical Industries Limited (TEVA)'s ROE is 0%, while industry's is 15.01%. The firm had revenue of $6.25 billion for the quarter, compared to the consensus estimate of $6.26 billion. During the same quarter in the previous year, the business posted $1.25 EPS. 06, 2017, but are collecting gains at -44.44% for the past six months.
Of Teva's second-quarter revenue of $5.7 billion, $3.1 billion came from generics, with $2.1 billion from its own branded drugs.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Metropolitan Life Ins New York holds 0.02% or 192,378 shares.
08/03/2017 - Teva Pharmaceutical Industries Limited was downgraded to "perform" by analysts at Oppenheimer.
Several research analysts have weighed in on the stock.
As such, the analyst maintains a Hold rating on TEVA stock with a price target of $15.50, representing a 16% dip below current trading levels. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover TEVA having a buy-equivalent rating. Citigroup maintained it with "Buy" rating and $86 target in Tuesday, July 28 report. Mizuho initiated Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Monday, December 7 with "Buy" rating.
According to the the latest analyst ratings which have been released, 1 brokers have issued a rating of "buy", 3 brokers "outperform", 19 brokers "hold", 3 brokers "underperform" and 0 brokers "sell".
It has some 21 specialty medicines for migraine, pain, respiratory and neurology in various stages of development, from early stage clinical trials to awaiting regulatory approval.
Want to see what other hedge funds are holding TEVA?